Canada Markets closed

Aequus Pharmaceuticals Inc. (AQS.V)

TSXV - TSXV Real Time Price. Currency in CAD
Add to watchlist
0.0250-0.0050 (-16.67%)
At close: 01:34PM EST
Full screen
Previous Close0.0300
Open0.0250
Bid0.0250 x 0
Ask0.0300 x 0
Day's Range0.0250 - 0.0250
52 Week Range0.0200 - 0.1200
Volume99,010
Avg. Volume54,322
Market Cap3.316M
Beta (5Y Monthly)0.61
PE Ratio (TTM)N/A
EPS (TTM)-0.0110
Earnings DateNov 01, 2022 - Nov 07, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est2.52
  • Simply Wall St.

    Aequus Pharmaceuticals Third Quarter 2022 Earnings: CA$0.004 loss per share (vs CA$0.003 loss in 3Q 2021)

    Aequus Pharmaceuticals ( CVE:AQS ) Third Quarter 2022 Results Key Financial Results Revenue: CA$347.9k (down 51% from...

  • GlobeNewswire

    Aequus Reports Third Quarter 2022 Financial Highlights

    VANCOUVER, British Columbia, Nov. 29, 2022 (GLOBE NEWSWIRE) -- Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”), a specialty pharmaceutical company with a focus on developing, advancing, and promoting differentiated products, today reported financial results for the quarter ended September 30, 2022 (“Third Quarter 2022”) and associated Company developments. Unless otherwise noted, all figures are in Canadian currency. Financial Report Highlights Aequus reported

  • GlobeNewswire

    Aequus Announces Sandoz Contract Expiry at Year End and Expected Health Canada Approval for Zimed® PF (Preservative Free)

    VANCOUVER, British Columbia, Nov. 29, 2022 (GLOBE NEWSWIRE) -- Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”), announced today that it has agreed to end its promotional service agreement with Sandoz Canada Inc. (“Sandoz”) on Tacrolimus Immediate Release (Immunosuppressant/Transplant) (“Tacrolimus IR”) and PrVistitan™ (bimatoprost 0.03% ophthalmic solution), effective December 31, 2022. Additionally, Aequus is expected to receive a “Notice of Compliance” from H